Long-term use of benzodiazepines and nonbenzodiazepine hypnotics, 1999-2014.
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Clinical guidelines suggest that benzodiazepines (BZDs) and non-BZD hypnotics (NBHs) be used on a short-term basis. The authors examined trends in long-term BZD and NBH use from 1999 to 2014. METHODS: Data included 82,091 respondents in the 1999-2014 waves of the National Health and Nutrition Examination Survey (NHANES). NHANES recorded medications used in the past 30 days on the basis of prescription bottles, and participants reported use duration. BZD and NBH use were categorized as short, medium, and long term, and time trends in use were assessed. RESULTS: BZD and NBH use increased from 1999 to 2014, driven by increases in medium- and long-term use, even after adjustment for age and race-ethnicity. In most years, only a fifth of current BZD or NBH users reported short-term use. CONCLUSIONS: Long-term BZD and NBH use has grown independent of U.S. demographic shifts. Monitoring of use is needed to prevent adverse outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a lack of access to CBTi has resulted in the majority of insomnia sufferers receiving prescriptions for sedative-hypnotic medications as the initial and ongoing treatment [12,13].”
From Co-morbid insomnia and sleep apnea (COMISA): Prevalence, consequences, methodological considerations, and recent randomized controlled trials (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Other studies using pharmaceutical claims data and the National Health and Nutrition Examination Survey support the conclusion that long-term benzodiazepine use may be a larger driver of the increased use of this class of medications.23,24”
From Patterns in Outpatient Benzodiazepine Prescribing in the United States (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965 · cited 1×
“In recently published treatment guidelines for chronic insomnia, the American College of Physicians recommended that these medications be used only on a short-term basis and only if behavioral treatments alone are ineffective (8).”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Pharmaceutical Overdose Deaths, United States, 2010
Jones, C. M., Mack, K. A., & Paulozzi, L. J. (2013) · JAMA · doi:10.1001/jama.2013.272 · Cited by 678
National Use of Prescription Medications for Insomnia: NHANES 1999-2010
Bertisch, S. M., Herzig, S. J., Winkelman, J. W., & Buettner, C. (2014) · Sleep · doi:10.5665/sleep.3410 · Cited by 305 · cited 2×
“(12), which used National Health andNutrition Examination Survey (NHANES) data; the authors found an increase in the prevalence of use of insomnia medications from 1999 to 2010.”
BackgroundMethodWilt, T. J., MacDonald, R., Brasure, M., Olson, C. M., Carlyle, M., Fuchs, E., Khawaja, I. S., Diem, S., Koffel, E., Ouellette, J., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1781 · Cited by 275 · cited 1×
“Concerns that long-term use may be associated with adverse outcomes (6) have prompted guidelines recommending use of these medications on a short-term basis (6,7).”
BackgroundZolpidem Use and Hip Fractures in Older People
Wang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., & Avorn, J. (2001) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2001.49280.x · Cited by 272 · cited 2×
“Studies show increased prescribing of medications commonly used for treatment of anxiety and sleep disorders, specifically benzodiazepines (BZDs) and non-BZD hypnotics (NBHs), since the early 1990s (1,2), despite concerns about adverse health outcomes associated with their use (3,4).”
BackgroundMojtabai, R., & Olfson, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08443 · Cited by 247 · cited 1×
“On the basis of a previous study (13), we categorized length of use into short term (less than six months), medium term (six to 24 months), and long term (more than 24 months).”
MethodSelf-citationFord, E. S., Wheaton, A. G., Cunningham, T. J., Giles, W. H., Chapman, D. P., & Croft, J. B. (2014) · Sleep · doi:10.5665/sleep.3914 · Cited by 213 · cited 2×
“Studies show increased prescribing of medications commonly used for treatment of anxiety and sleep disorders, specifically benzodiazepines (BZDs) and non-BZD hypnotics (NBHs), since the early 1990s (1,2), despite concerns about adverse health outcomes associated with their use (3,4).”
BackgroundTrends in prescribing of sedative-hypnotic medications in the USA: 1993-2010.
Kaufmann, C. N., Spira, A. P., Alexander, G. C., Rutkow, L., & Mojtabai, R. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3951 · Cited by 105 · cited 4×
“Studies show increased prescribing of medications commonly used for treatment of anxiety and sleep disorders, specifically benzodiazepines (BZDs) and non-BZD hypnotics (NBHs), since the early 1990s (1,2), despite concerns about adverse health outcomes associated with their use (3,4).”
BackgroundMethodInfluential
Research works printed but not linked: 2
- National Institute for Health and Care Excellence Generalised anxiety disorder and panic disorder in adults: management [Internet] 2011 Available from: https://www.nice.org.uk/guidance/cg113/resources/generalised-anxiety-disorder-and-panic-disorder-in-adults-management-pdf-35109387756997 31961629
- Ortman JM Velkoff VA An aging nation: the older population in the United States Washington 2014
Cited by
Benzodiazepine Use and Misuse Among Adults in the United States
Maust, D. T., Lin, L. A., & Blow, F. C. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800321 · Cited by 337
Patterns in Outpatient Benzodiazepine Prescribing in the United States
Agarwal, S. D., & Landon, B. E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.7399 · Cited by 319
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
“Total BZD use actually increased from 1999 to 2014, largely driven by increases in long-term use [16].”
BackgroundSweetman, A., Lack, L., & Bastien, C. (2019) · Brain Sciences · doi:10.3390/brainsci9120371 · Cited by 253
“Although cognitive and behavioral therapy for insomnia (CBTi) leads to long-term improvement of insomnia and is the recommended ‘first line’ insomnia treatment [8–11], a lack of access to CBTi has resulted in the majority of insomnia sufferers receiving prescriptions for sedative-hypnotic medications as the initial an…”
BackgroundRecent advances in synthesis and medicinal chemistry of benzodiazepines
Arora, N., Dhiman, P., Kumar, S., Singh, G., & Monga, V. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103668 · Cited by 114
An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics
Janto, K., Prichard, J. R., & Pusalavidyasagar, S. S. (2018) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7282 · Cited by 102
“23 Data from the National Center for Health Statistics 2005–2010 show that more than 4% of United States adults older than 19 years have reported prescription sleep aid use in the past month.”
Multicomponent reactions as a potent tool for the synthesis of benzodiazepines
Farhid, H., Khodkari, V., Nazeri, M. T., Javanbakht, S., & Shaabani, A. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02600j · Cited by 103
Designer Benzodiazepines: A Review of Toxicology and Public Health Risks
Brunetti, P., Giorgetti, R., Tagliabracci, A., Huestis, M. A., & Busardò, F. P. (2021) · Pharmaceuticals · doi:10.3390/ph14060560 · Cited by 111
Torres-Bondia, F., de Batlle, J., Galván, L., Buti, M., Barbé, F., & Piñol-Ripoll, G. (2020) · BMC Public Health · doi:10.1186/s12889-020-08984-z · Cited by 69
Sweetman, A., Putland, S., Lack, L., McEvoy, R. D., Adams, R., Grunstein, R., Stocks, N., Kaambwa, B., Van Ryswyk, E., Gordon, C., et al. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101404 · Cited by 62
Prescription and Nonprescription Sleep Product Use Among Older Adults in the United States
Maust, D. T., Solway, E. S., Clark, S. J., Kirch, M., Singer, D., & Malani, P. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.09.004 · Cited by 54
Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000316 · Cited by 50
Woods, A., Begum, M., González‐Chica, D. A., Bernardo, C., Hoon, E. A., & Stocks, N. P. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.896 · Cited by 54
Perspectives on increasing the impact and reach of CBT-I
Manber, R., Simpson, N. S., & Gumport, N. B. (2023) · SLEEP · doi:10.1093/sleep/zsad168 · Cited by 46
Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey
Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221082386 · Cited by 40
Trends in sleep problems and patterns among Japanese adolescents: 2004 to 2017
Otsuka, Y., Kaneita, Y., Spira, A. P., Mojtabai, R., Itani, O., Jike, M., Higuchi, S., Kanda, H., Kuwabara, Y., Kinjo, A., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100107 · Cited by 49
Zuo, L., Chen, X., Liu, M., Dong, S., Chen, L., Li, G., Zhai, Z., Zhou, L., Chen, H., Wei, Y., et al. (2022) · Sleep Health · doi:10.1016/j.sleh.2022.07.004 · Cited by 40
Tubbs, A. S., Fernandez, F., Ghani, S. B., Karp, J. F., Patel, S. I., Parthasarathy, S., & Grandner, M. A. (2021) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.9096 · Cited by 38
Ray, W. A., Chung, C. P., Murray, K. T., Malow, B. A., Daugherty, J. R., & Stein, C. M. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003709 · Cited by 39
Reappraising the use of benzodiazepines in chronic pain patients
Pergolizzi, J. V., & LeQuang, J. A. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1725352 · Cited by 33
Prescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents
Bushnell, G., Crystal, S., & Olfson, M. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.07.006 · Cited by 29
Discontinuation of Chronic Benzodiazepine Use Among Adults in the United States
Gerlach, L. B., Strominger, J., Kim, H. M., & Maust, D. T. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05098-0 · Cited by 29
BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights
Zaami, S., Graziano, S., Tittarelli, R., Beck, R., & Marinelli, E. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917145636 · Cited by 27
Implementation of a digital cognitive behavioral therapy for insomnia pathway in primary care
Sweetman, A., Knieriemen, A., Hoon, E. A., Frank, O., Stocks, N. P., Natsky, A. N., Kaambwa, B., Vakulin, A., Lovato, N., Adams, R., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106484 · Cited by 24
Emergency Department Visits Attributed to Adverse Events Involving Benzodiazepines, 2016–2017
Moro, R. N., Geller, A. I., Weidle, N. J., Lind, J. N., Lovegrove, M. C., Rose, K. O., Goring, S. K., McAninch, J., Dowell, D., & Budnitz, D. S. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.11.017 · Cited by 21
Li, J., Ran, X., Cui, C., Xiang, C., Zhang, A., & Shen, F. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6123 · Cited by 22
Lonchampt, S., Gerber, F., Aubry, J., Desmeules, J. A., Kosel, M., & Besson, M. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.614825 · Cited by 21
“The long-term prescription of benzodiazepines, mainly for sleep problems and anxiety, is also common in the general population although it is associated with dependency and adverse events (47, 48).”
BackgroundBenzodiazepine Use and Dependence in Relation to Chronic Pain Intensity and Pain Catastrophizing
Lape, E. C., Powers, J. M., Hooker, J. E., Edwards, R. R., & Ditre, J. W. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.09.019 · Cited by 22
1,4-Benzodiazepines and New Derivatives: Description, Analysis, and Organic Synthesis
Batlle, E., Lizano, E., Viñas, M., & Pujol, M. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79879 · Cited by 26
“In fact, the total BZD use increased from 1999 to 2014, mainly caused by the augmentation of the long-term inappropriate users [12].”
BackgroundMapping the insomnia patient journey in Europe and Canada
O'Regan, D. J., García-Borreguero, D., Gloggner, F., Wild, I., Leontiou, C., & Ferini‐Strambi, L. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1233201 · Cited by 21
Palamar, J. J., Han, B. H., & Martins, S. S. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.11.015 · Cited by 14
“in multiple waves of NHANES, which found that prevalence of use of these medications increased between 1999 and 2014 (Kaufmann et al., 2018).”
BackgroundInoue, Y., Takaesu, Y., & Koebis, M. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03196-0 · Cited by 14
“A study associated with the United States National Health and Nutrition Examination Survey (NHANES) found that a growing proportion of patients received long-term prescriptions of BZDs, with about 3% receiving a prescription for 6 months or longer [1].”
BackgroundBenzodiazepine and unhealthy alcohol use among adult outpatients.
Hirschtritt, M. E., Palzes, V. A., Kline‐Simon, A. H., Kroenke, K., Campbell, C. I., & Sterling, S. (2019) · PubMed · Cited by 23
Declining trend in use of medications for sleep disturbance in the United States from 2013 to 2018
Kaufmann, C. N., Spira, A. P., Wickwire, E. M., Mojtabai, R., Ancoli‐Israel, S., Fung, C. H., & Malhotra, A. (2022) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10132 · Cited by 12
Benzodiazepine usage and patient preference for alternative therapies: A descriptive study
Sake, F., WONG, K. K. H., Bartlett, D. J., & Saini, B. (2019) · Health Science Reports · doi:10.1002/hsr2.116 · Cited by 13
“2% in 2013‐2014), mostly driven by medium to long‐term users.(22) Although there has been a modest decline in the volume of benzodiazepine prescriptions dispensed annually, overall, there is still a high level of long‐term benzodiazepine use in Australia.”
BackgroundMak, S. S., Alessi, C. A., Kaufmann, C. N., Martin, J. L., Mitchell, M. N., Ulmer, C., Lum, H. D., McCarthy, M. S., Smith, J. P., & Fung, C. H. (2024) · Clinical Gerontologist · doi:10.1080/07317115.2022.2130849 · Cited by 10
“Sleep problems and insomnia are reported by almost half of older adults and a majority of US veterans (Jenkins et al., 2015; Kaufmann, Spira, Depp, & Mojtabai, 2018; Patel, Steinberg, & Patel, 2018).”
Self-citationTubbs, A. S., Ghani, S. B., Naps, M. S., Grandner, M. A., Stein, M. D., & Chakravorty, S. (2021) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.9724 · Cited by 13
“Sedative-hypnotic medications are a common treatment for sleep disturbances, 19 – 21 even among persons who use opioids.”
González‐Chica, D. A., Begum, M., Bernardo, C., Hoon, E. A., Sweetman, A., & Stocks, N. P. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13561 · Cited by 8
“and long-acting BZD prescriptions increased between 2003 and 2015 [12, 26].”
BackgroundKaufmann, C. N., Moore, A. A., Bondi, M. W., Murphy, J. D., Malhotra, A., & Hart, L. A. (2020) · Current Sleep Medicine Reports · doi:10.1007/s40675-020-00163-1 · Cited by 10
Tanielian, M., Antoun, J., Sidani, M., Halabi, A., Hoballah, M. M., Hawatian, K., & Assaf, G. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01707-w · Cited by 11
“The younger age group is more likely to continue long-term hypnotics use into older age as studies have shown that more than half of chronic insomnia patients who are started on hypnotics are likely to continue taking them long-term [49].”
BackgroundWang, X., Zhong, Y., Wang, R., Zhang, D., Li, Y., Pan, Y., & Li, Y. (2025) · Psychology Research and Behavior Management · doi:10.2147/prbm.s516062 · Cited by 9
Chen, C., Hennessy, S., Brensinger, C. M., Acton, E. K., Bilker, W. B., Chung, S. P., Dawwas, G. K., Horn, J. R., Miano, T. A., Nguyen, T. P. P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19551-4 · Cited by 9
“, were exposed to the base pair); (4) experienced an outcome event during the continuous exposure to the base pair; and (5) used at least one valid candidate interacting precipitant drug (see “Exposure”).”
The incidence of new and persistent benzodiazepine use after surgery
Albertsson, Þ. Í., Jónsdóttir, F., Kárason, S., & Sigurdsson, M. I. (2023) · Surgery · doi:10.1016/j.surg.2022.12.024 · Cited by 8
Gutierrez, G., Chowdhary, A., Hartogensis, W., Soltani, S., Chao, M. T., & Mason, A. E. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.108696 · Cited by 5
Weleff, J., Anand, A., Squeri, M., Sieke, R., Thompson, N. R., & Barnett, B. S. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2191610 · Cited by 9
“…(Blanco et al. 2018; De Las Cuevas et al. 1999; Escrivá Ferrairó et al. 2000; Nordfjærn et al. 2014), race (White, Black, other) (Cook et al. 2019; Kaufmann et al. 2018), marital status (married/partnered, single, divorced/separated, widowed) (Blanco et al. 2018; De Las Cuevas et al. 1999),…”
BackgroundResultChalet, F.-X., Luyet, P., Rabasa, C., Vaillant, C., Saskin, P., Ahuja, A., & Citrome, L. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2359891 · Cited by 5
Tardelli, V. S., Fidalgo, T. M., & Martins, S. S. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106606 · Cited by 25
“, 2009), this likely explains simultaneous raises in their long-term and non-medical use (Kaufmann et al., 2018).”
BackgroundSleep disturbances in bereaved older people: a review of the literature
Godzik, C. M. (2020) · Mental Health Practice · doi:10.7748/mhp.2020.e1492 · Cited by 6
The Role of Mindfulness in the Insomnia Severity of Female Chronic Hypnotic Users
Curado, D. F., de Barros, V. V., Opaleye, E. S., Bowen, S. W., Hachul, H., & Noto, A. R. (2018) · International Journal of Behavioral Medicine · doi:10.1007/s12529-018-9724-1 · Cited by 6
Norouzi, M., Nazeri, M. T., Shaabani, A., & Notash, B. (2024) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.20.241 · Cited by 4
Patterns of Polydrug Use in Patients Presenting at the Emergency Department with Acute Intoxication
Manjón-Prado, H., Santos, E. S., & Osuna, E. (2025) · Toxics · doi:10.3390/toxics13050380 · Cited by 5
Predicting Hypnotic Use among Insomnia Patients with the Theory of Planned Behavior and Craving
Yang, C., Lai, Y.-S., Huang, Y., Huang, Y.-C., & Lee, H. (2022) · Behavioral Sciences · doi:10.3390/bs12070209 · Cited by 4
“Another study in the United States also showed a significant increasing trend of hypnotic use from 1999 to 2014 in medium- and long-term use (at least >6 months), but not in short-term use [23].”
BackgroundChapman, C. A., Povysheva, N. V., Tarr, T. B., Nuwer, J. L., Meriney, S. D., Johnson, J. W., & Jacob, T. C. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1624813 · Cited by 4
“This was followed by secondary antibody incubation and DAPI nuclear staining.”
Xu, X., Wang, X., Zhong, N., Xu, J., Li, C., Wang, G., Wang, W., Ye, Y., Chen, Y., Liu, T., et al. (2022) · BJPsych Open · doi:10.1192/bjo.2022.589 · Cited by 4
Tully, I. A., Kim, J. P., Simpson, N. S., Palaniappan, L. P., Tutek, J., Gumport, N. B., Dietch, J. R., & Manber, R. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10552 · Cited by 6
Dose–response association of benzodiazepine use and development of deep vein thrombosis
Shih, N.-C., Yeh, L., Wang, B.-Y., Yang, S., Yang, S.-F., & Yeh, C. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115553 · Cited by 4
Allary, A., Proulx-Tremblay, V., Bélanger, C., Hudon, C., O’Connor, K. P., Roberge, P., Vasiliadis, H., Desrosiers, C., Cruz-Santiago, D., & Grenier, S. (2024) · Aging & Mental Health · doi:10.1080/13607863.2024.2372473 · Cited by 3
“Moreover, in the United States, BZD and non-benzodiazepine hypnotic prescriptions have increased in the past few decades (Agarwal & Landon, 2019; Bachhuber et al., 2016; Kaufmann et al., 2018; Maust et al., 2017, 2019), driven by increases in medium-and long-term use.”
Mother's little helper turned a foe: Alprazolam use, misuse, and abuse
Cardona-Acosta, A. M., Meisser, N., Vardeleon, N. I., Steiner, H., & Bolaños‐Guzmán, C. A. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111137 · Cited by 5
Major Depression and Sedative-Hypnotic Use Disorder: a Review
Chen, L., Kaufmann, C. N., & Mojtabai, R. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0218-7 · Cited by 4
Initial validation of the expectancies for Benzodiazepine Analgesia Scale.
Lape, E. C., Powers, J. M., LaRowe, L. R., & Ditre, J. W. (2023) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000692 · Cited by 4
Missbrauch und Abhängigkeit von Benzodiazepinen und Z-Drugs: Klinik und Therapie
Soyka, M. (2021) · Nervenheilkunde · doi:10.1055/a-1523-5718 · Cited by 7
“Von 1999 bis 2014 war der Konsum von BZD- und Non-BZD-Hypnotika in den USA deutlich gestiegen, vor allem wegen häufigerer Langzeitverschreibungen [35].”
BackgroundInfluentialAssessing suicide risk in chronic pain management: a narrative review across drug classes
Brezić, N., Gligorevic, S., Candido, K. D., & Knežević, N. N. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2391999 · Cited by 2
Chirica, M. G., Adams, S. M., Quinn, P. D., Meraz, R., Rickert, M. E., Sidorchuk, A., Kroenke, K., & D'Onofrio, B. M. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.02.065 · Cited by 3
Takamine, L. H., Krein, S. L., Ratliff, E., Strominger, J., Virk, A., & Maust, D. T. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08385-z · Cited by 3
“The growth in BZD use that is long-term 30 means that efforts to limit BZD prescribing cannot only focus on limiting new prescriptions, but requires discontinuing therapy among prevalent users for whom use may no longer be appropriate.”
Benzotriazepine synthesis, conformational analysis, and biological properties
Harvey, S.-M., Wei, X., Truong, D., & Lubell, W. D. (2024) · Canadian Journal of Chemistry · doi:10.1139/cjc-2023-0146 · Cited by 2
Benzodiazepine Therapy: The Good, the Bad, and the Ugly
Guina, J., Merrill, B., & LeQuang, J. A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780197517277.003.0003 · Cited by 2
Saffore, C. D., Pickard, A. S., Crawford, S. Y., Fischer, M. A., Sharp, L. K., Pointer, S., & Lee, T. A. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1900989 · Cited by 3
Lee, S., Kaufmann, C. N., Lippi, C. A., Ryan, S. J., & Guo, Y. M. (2025) · Sleep Health · doi:10.1016/j.sleh.2025.01.002 · Cited by 1
Kusumoto, H., Khakharia, A., Bramoweth, A. D., Phillips, L. S., Fung, C. H., Eisenstein, R., & Vaughan, C. P. (2025) · Journal of Applied Gerontology · doi:10.1177/07334648251330666 · Cited by 1
Tordjman, L., Goltzène, M.-A., & Ruppert, É. (2025) · Sleep Health · doi:10.1016/j.sleh.2025.07.002 · Cited by 3
Chapman, C. A., Povysheva, N. V., Johnson, J. W., & Jacob, T. C. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110624 · Cited by 2
“Despite these risks, long-term use among patients is highly prevalent (Kaufmann et al., 2018; Kurko et al., 2015; Maust et al., 2019; Olfson et al., 2015; Tanguay Bernard et al., 2018) and relapse rates are high (Chapoutot et al., 2021; Gerlach et al., 2019; Morin et al., 2005), underscoring a…”
Liu, N., Li, S., Zhang, K.-Y., & Wang, L. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143577 · Cited by 1
Bruyneel, M., Rozenberg, S., Sanida, C., Demaeyer, N., Emilie, C., & Bruyneel, A.-V. (2026) · Sleep Medicine · doi:10.1016/j.sleep.2026.109040 · Cited by 2
Cummins, J. A., Gottlieb, D. J., Sofer, T., & Wallace, D. A. (2024) · Journal of Medical Internet Research · doi:10.2196/58902 · Cited by 2
“A subsequent analysis of US data from the 1999-2014 National Health and Nutrition Examination Survey supported an increase in benzodiazepine use, which appeared to be driven by medium-and long-term use of the medications [27].”
Part I: Interactive case: Rational deprescribing of benzodiazepine receptor agonists for insomnia
Farrell, B. J. (2022) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1612
Swanson, L. N., Jones, L. S., Aycart, J. M., Zhu, Z., Rabin, D. M., & Kuhn, T. P. (2024) · medRxiv · doi:10.1101/2024.01.30.24301798
“29,30 Given the high dependence and addiction potential of benzodiazepines, as well as the severe and potentially life-threatening effects associated with withdrawal, 9 our findings provide preliminary evidence for the potential of ketamine as a safer alternative in specific contexts.”
Stimulus Control Therapy for Insomnia
Pires, M. L. N., & Sousa, K. M. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-50710-6_11
Characteristics and predictors of prescription sleep medication use among veterans with chronic pain
Li, Y. I., Chen, C., Michel, M., Donovan, L. M., Zeliadt, S. B., & Chen, J. A. (2025) · PAIN Reports · doi:10.1097/pr9.0000000000001264
“47 However, there is a lack of widespread access to CBT-I, and patients are more commonly prescribed sleep medications for insomnia, 25 despite many sleep medications carrying significant side effects and indications for short-term use only.”
Diagnosis, treatment, and associated outcomes of later-life insomnia: a narrative review
Kaufmann, C. N., Lee, S., Berkley, A., Wickwire, E. M., Neubauer, D. N., Li, J., & Spira, A. P. (2025) · SLEEP · doi:10.1093/sleep/zsaf192
Zarei, N., & Marandi, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-24165-7
Chapter 7. Sedatives, Hypnotics, or Anxiolytics
Blazes, C. K., & Leung, S. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg07
Kaufmann, C. N., Spira, A. P., Tseng, C., & Wickwire, E. M. (2025) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2025.101333
Benzodiazepine use : a two-way relationship with work accidents and impact of COVID-19 pandemic
Baudot, F.-O. (2022) · theses.fr (ABES) · doi:10.70675/88942d7fzaddbz4b8cz91b9zcc0b92de1598
Norman, C., Acreman, D., Bissram, M., Curtis, B., Hamer, S., Westphal, F., Pütz, M., Stefan, C., Delaney, S. R., Lines, R., et al. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04433-9
“Long-term use of BZDs is common (Cadogan et al. 2018 ; Kaufmann et al. 2018; López-Pelayo et al. 2019; Murphy et al. 2016) despite prescription guidelines discouraging this due to the high risk of physical dependence and addiction (National Institute for Health and Care Excellence, 2020; The Royal…”
Hartung, D. M., Servid, S. A., Middleton, L., Klein, T., Geddes, J., Anderson, T. S., & Park, T. W. (2026) · Medical Care · doi:10.1097/mlr.0000000000002360
Metadata
- Authors
- Kaufmann, C. N., Spira, A. P., Depp, C. A., & Mojtabai, R.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Psychiatric Services
- Published
- 2018-02-01
- Volume
- 69
- Issue
- 2
- Pages
- 235-238
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- PMC
- PMC5794624
- OpenAlex
- W2767159911
- Cited by
- 85
- References
- 13
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 13 · 2020: 10 · 2019: 7 · 2018: 8
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (T32MH019934)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, non-benzodiazepine hypnotics, chronic drug administration, sleep medication use, temporal trends, prescription drug use, NHANES, adverse drug outcomes
- MeSH terms
- Adolescent, Adult, Aged, Benzodiazepines, Drug Utilization, Female, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Nutrition Surveys, Drug Prescriptions, United States, Logistic Models, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.